First Oc Dermatology
First Oc Dermatology
Fountain Valley, California, United States16 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Recruiting | Phase 1 | 2026-10-09 | NCT07049575 | |
| A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | Nonsegmental Vitiligo | Recruiting | Phase 2 | 2026-09-30 | NCT07108283 | |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06143878 | |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06095115 | |
| A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus | Cutaneous Lichen Planus, Lichenoid Eruptions, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, lichen planus, skin disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07775924 | |
| A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-09-25 | NCT07230860 | |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-09-25 | NCT06934226 | |
| A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Phase 3 | 2026-09-25 | NCT06868212 | |
| A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Recruiting | Phase 2 | 2026-09-09 | NCT07431177 | |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Enrolling by invitation | Phase 3 | 2026-07-30 | NCT05735483 | |
| A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 3 | 2026-07-30 | NCT05559359 | |
| Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-06-15 | NCT06397911 | |
| Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | Plaque Psoriasis | Active, not recruiting | Phase 3 | 2026-04-17 | NCT05172726 | |
| A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC | Bacterial Infections and Mycoses, Chronic Disease, Chronic Spontaneous Urticaria, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Hypersensitivity, Immediate, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Suppuration, alopecia, alopecia areata, atopic eczema, bacterial infectious disease, chronic urticaria, dermatitis, disorder of pilosebaceous unit, hereditary disease, hereditary skin disorder, hidradenitis, hidradenitis suppurativa, hypopigmentation of the skin, hypotrichosis, immune system disorder, psoriasis, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, skin pigmentation disorder, skin vascular disease, sweat gland disorder, urticaria, vitiligo | Active, not recruiting | Not stated | 2026-03-20 | NCT03661866 | |
| Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). | Superficial Basal Cell Carcinoma | Active, not recruiting | Phase 3 | 2026-01-14 | NCT03573401 | |
| Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2024-10-03 | NCT05509023 |